Cite
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
MLA
Langdahl, Bente, et al. “Romosozumab Efficacy and Safety in European Patients Enrolled in the FRAME Trial.” Osteoporosis International, vol. 33, no. 12, Dec. 2022, pp. 2527–36. EBSCOhost, https://doi.org/10.1007/s00198-022-06544-2.
APA
Langdahl, B., Hofbauer, L. C., Ferrari, S., Wang, Z., Fahrleitner-Pammer, A., Gielen, E., Lakatos, P., Czerwinski, E., Gimeno, E. J., Timoshanko, J., Oates, M., & Libanati, C. (2022). Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporosis International, 33(12), 2527–2536. https://doi.org/10.1007/s00198-022-06544-2
Chicago
Langdahl, Bente, Lorenz C. Hofbauer, Serge Ferrari, Zhenxun Wang, Astrid Fahrleitner-Pammer, Evelien Gielen, Péter Lakatos, et al. 2022. “Romosozumab Efficacy and Safety in European Patients Enrolled in the FRAME Trial.” Osteoporosis International 33 (12): 2527–36. doi:10.1007/s00198-022-06544-2.